LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.625
-0.005 (-0.31%)
Oct 31, 2025, 4:00 PM EDT - Market closed
LAVA Therapeutics Revenue
LAVA Therapeutics had revenue of $4.99M in the twelve months ending June 30, 2025, down -32.55% year-over-year. In the year 2024, LAVA Therapeutics had annual revenue of $11.98M with 77.01% growth.
Revenue (ttm)
$4.99M
Revenue Growth
-32.55%
P/S Ratio
8.75
Revenue / Employee
$146,765
Employees
34
Market Cap
42.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.98M | 5.21M | 77.01% |
| Dec 31, 2023 | 6.77M | -12.62M | -65.09% |
| Dec 31, 2022 | 19.39M | 14.04M | 262.45% |
| Dec 31, 2021 | 5.35M | 1.60M | 42.78% |
| Dec 31, 2020 | 3.75M | - | - |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
LVTX News
- 4 weeks ago - LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 - GlobeNewsWire
- 2 months ago - LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - LAVA Reports First Quarter 2025 Financial Results, Provides Business Update - GlobeNewsWire
- 7 months ago - LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewsWire
- 7 months ago - LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 8 months ago - Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga
- 10 months ago - LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewsWire
- 11 months ago - LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 - GlobeNewsWire